Company research
Aprea Therapeutics, Inc.
CIK 1781983Updated Nov 21, 2026
APRE price & chart
Loading TradingView…
NASDAQ:APRE on TradingView ↗About the company
Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pursuing an approach to treating cancer that seeks to exploit vulnerabilities associated with cancer cell mutations. This approach is designed to kill tumor cells while minimizing the effect on normal, healthy cells. Aprea believes its technology has potential applications across multiple cancer types, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead program is APR-1051, an oral, small molecule inhibitor of WEE1 kinase, currently in a Phase 1 clinical trial. The Company’s second clinical-stage product candidate, ATRN-119, is a small molecule ATR inhibitor for which the Company has completed a Phase 1 dose-escalation study and is exploring combination approaches. For more information, please visit the Company’s website at www.aprea.com.
In the news
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ↗
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,321,316Source | 26,893,969Source | 42,289,924Source | 17,309,710Source | 29,964,587Source | 47,612,387Source | 20,222,083Source | 33,200,006Source | 15,933,401Source | 23,979,493Source | 22,650,174Source | 30,155,827Source |
| Property, Plant and Equipment, NetUSD | 65,236Source | 86,950Source | 64,033Source | 70,665Source | 92,379Source | 54,379Source | 76,093Source | 90,183Source | 59,807Source | 81,522Source | 88,362Source | 2,321Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,718,052Source | 26,249,625Source | 41,233,428Source | 16,532,199Source | 28,694,694Source | 46,466,202Source | 19,275,721Source | 32,369,973Source | 14,599,347Source | 22,849,885Source | 21,606,820Source | 28,786,647Source |
| Assets, CurrentUSD | 13,943,988Source | 26,483,820Source | 41,913,114Source | 16,927,210Source | 29,559,786Source | 47,245,440Source | 19,834,410Source | 33,068,837Source | 15,561,246Source | 23,576,139Source | 22,521,095Source | 30,153,506Source |
| Prepaid Expense and Other Assets, CurrentUSD | 225,936Source | 234,195Source | 679,686Source | 395,011Source | 865,092Source | 779,238Source | 558,689Source | 698,864Source | 961,899Source | 726,254Source | 914,275Source | 1,366,859Source |
| Other Assets, NoncurrentUSD | 271,162Source | 281,662Source | 271,162Source | 271,162Source | 271,162Source | 271,162Source | 271,162Source | — | 271,162Source | 281,662Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 3,201,086Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,979Source | 5,435Source | 12,391Source | 5,752Source | 5,430Source | 11,983Source | 5,513Source | 5,430Source | 8,192Source | 5,481Source | 3,736Source | 2,655Source |
| Additional Paid in CapitalUSD | 352,722,214Source | 350,693,403Source | 389,596,149Source | 352,250,747Source | 350,545,473Source | 389,631,454Source | 351,145,676Source | 350,438,045Source | 356,709,645Source | 350,971,225Source | 335,644,204Source | 330,060,836Source |
| Retained Earnings (Accumulated Deficit)USD | -331,185,811Source | -318,147,073Source | -340,520,662Source | -328,213,401Source | -314,363,304Source | -336,929,358Source | -324,974,531Source | -310,893,252Source | -333,641,441Source | -321,041,872Source | -308,083,161Source | -293,796,405Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -10,629,534Source | -10,604,747Source | -10,617,617Source | -10,628,417Source | -10,628,304Source | -10,625,700Source | -10,626,736Source | -10,626,356Source | -10,634,714Source | -10,627,379Source | -10,611,273Source | -10,623,408Source |
| Stockholders' Equity Attributable to ParentUSD | 10,912,848Source | 21,947,018Source | 38,470,261Source | 13,414,681Source | 25,559,295Source | 41,588,380Source | 15,549,922Source | 28,923,867Source | 12,441,682Source | 19,307,455Source | 16,953,506Source | 25,643,678Source |
| Liabilities and EquityUSD | 14,321,316Source | 26,893,969Source | 42,289,924Source | 17,309,710Source | 29,964,587Source | 47,612,387Source | 20,222,083Source | 33,200,006Source | 15,933,401Source | 23,979,493Source | 22,650,174Source | 30,155,827Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,681,107Source | 3,635,888Source | 3,092,302Source | 3,167,668Source | 3,094,229Source | 5,296,646Source | 3,361,098Source | 2,965,076Source | 2,764,358Source | 3,360,975Source | 4,385,605Source | 3,201,086Source |
| Accounts Payable, CurrentUSD | 641,322Source | 1,153,880Source | 935,139Source | 1,195,838Source | 964,327Source | 2,940,756Source | 1,281,651Source | 1,318,385Source | 713,668Source | 1,352,240Source | 1,670,369Source | 842,754Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | — | — | — | — | 50,739Source | — | — | 148,405Source | — | — | 528,974Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -3,287,917Source | -3,932,659Source | -12,599,569Source | -12,958,711Source | -14,286,756Source | -112,662,027Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 5,428Source | 5,429Source | 21,715Source | 22,318Source | 7,052Source | 4,403Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 32,525Source | -71,935Source | -646,701Source | -314,207Source | 827,463Source | -858,513Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,756,726Source | -3,631,163Source | -12,894,439Source | -13,556,718Source | -12,177,608Source | -25,011,136Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | -15,478Source | -93,093Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 15,478Source | 93,093Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 34,624,149Source | 55,849Source | 4,640,238Source | 14,821,895Source | 5,139,990Source | 682,973Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 13,758,982Source | 26,291,162Source | 41,275,043Source | 16,572,872Source | 46,507,608Source | 19,316,139Source | 14,640,533Source | 22,890,055Source | 21,647,537Source | 28,786,647Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -5,691Source | -35,494Source | 2,953Source | -29,124Source | 7,711Source | -51,803Source | -95,319Source | 71,800Source | -38,926Source | 281,534Source |
| General and Administrative ExpenseUSD | — | — | 1,480,319Source | 1,605,238Source | 1,570,138Source | 1,593,671Source | 1,819,245Source | 1,764,979Source | 6,476,560Source | 6,458,699Source | 8,427,703Source | 20,969,771Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,972,410Source | -3,783,769Source | -3,591,304Source | -3,238,870Source | -3,287,917Source | -3,932,659Source | -12,599,569Source | -12,958,711Source | -14,286,756Source | -112,662,027Source |
| Operating ExpensesUSD | — | — | 3,119,236Source | 4,451,637Source | 4,032,180Source | 3,505,884Source | 3,430,412Source | 4,248,045Source | 13,519,595Source | 15,822,236Source | 16,055,194Source | 113,392,228Source |
| Other Nonoperating Income (Expense)USD | — | — | 144,978Source | 313,247Source | 440,876Source | 148,903Source | 142,495Source | 152,923Source | 634,267Source | 1,360,944Source | 1,185,207Source | 730,201Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 35,098,813Source | 59,234Source | 5,047,606Source | 16,140,356Source | 5,788,918Source | 682,973Source |
| Share-based Payment Arrangement, Expense | — | — | —Source | — | —Source | —Source | — | —Source | — | — | — | — |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,117,388Source | -4,097,016Source | -4,032,180Source | -3,387,773Source | -3,430,412Source | -4,085,582Source | -13,233,836Source | -14,319,655Source | -15,471,963Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 144,978Source | 313,247Source | 440,876Source | 148,903Source | 142,495Source | 152,923Source | 634,267Source | 1,360,944Source | 1,185,207Source | 730,201Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,972,410Source | -3,783,769Source | -3,591,304Source | -3,238,870Source | -3,287,917Source | -3,932,659Source | -12,599,569Source | -12,958,711Source | -14,286,756Source | -112,662,027Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.47Source | -0.64Source | -0.07Source | -0.53Source | -0.22Source | -0.66Source | -1.93Source | -2.35Source | -3.95Source | -67.99Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.47Source | -0.64Source | -0.07Source | -0.53Source | -0.22Source | -0.66Source | -1.93Source | -2.45Source | -3.95Source | -68.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 6,372,938Source | 5,939,755Source | 53,483,504Source | 6,083,329Source | 14,685,448Source | 5,993,866Source | 6,538,722Source | 5,509,921Source | 3,617,607Source | 1,657,055Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 6,372,938Source | 5,939,755Source | 53,483,504Source | 6,083,329Source | 14,685,448Source | 5,993,866Source | 6,538,722Source | 5,509,921Source | 3,617,607Source | 1,657,055Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -5,691Source | -35,494Source | 2,953Source | -29,124Source | 7,711Source | -51,803Source | -95,319Source | 71,800Source | -38,926Source | 281,534Source |
| General and Administrative ExpenseUSD | — | — | 1,480,319Source | 1,605,238Source | 1,570,138Source | 1,593,671Source | 1,819,245Source | 1,764,979Source | 6,476,560Source | 6,458,699Source | 8,427,703Source | 20,969,771Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 150,669Source | 348,741Source | 358,923Source | 178,027Source | 134,784Source | 204,726Source | 652,086Source | 1,289,144Source | 1,224,133Source | 448,667Source |
| Operating ExpensesUSD | — | — | 3,119,236Source | 4,451,637Source | 4,032,180Source | 3,505,884Source | 3,430,412Source | 4,248,045Source | 13,519,595Source | 15,822,236Source | 16,055,194Source | 113,392,228Source |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-295247
Registration 333-293609
Filing attachments
tm2630244d1_ex99-1.htm · 8-K · 2026-11-20
Exhibit 99.1 Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration Planned expansion …
Read attachment ↗tm2630244d1_ex99-2.htm · 8-K · 2026-11-20
Exhibit 99.2 1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers November 2026 ───────────────────────────────────────────────────────── 2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements…
Read attachment ↗tm2628880d1_ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Aprea Therapeutics Announces Third Quarter 2026 Financial Results Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026 APR-1051 Phase 1 clinical trial expanded to nine sites, with immunohistochemistry (IHC) testing for Cyclin E expression now in place to support biomarker assessment and future patient selection strategies $37.8 million in cash and cas…
Read attachment ↗tm2628880d1_ex99-2.htm · 8-K · 2026-11-04
Exhibit 99.2 1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers November 2026 ───────────────────────────────────────────────────────── 2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements…
Read attachment ↗apre-20260828xex99d1.htm · 8-K · 2026-08-28
EX-99.1 2 apre-20260828xex99d1.htm EX-99.1 Exhibit 99.1 Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents DOYLESTOWN, PA, August 28, 2026 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapie…
Read attachment ↗apre-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Aprea Therapeutics Announces Second Quarter 2026 Financial Results Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and Cyclin E - overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head an…
Read attachment ↗